# Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy

> **NCT01128114** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Acute Bipolar Mania

## Interventions

- **DRUG:** Quetiapine fumarate (Seroquel XR)

## Key facts

- **NCT ID:** NCT01128114
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2012-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128114, "Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01128114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*